IMC-A12: Phase II started

ImClone began an open-label, U.S. Phase II trial to evaluate weekly 6 mg/kg doses of intravenous IMC-A12 or IMC-1121B in combination with mitoxantrone every 3 weeks and oral prednisone given daily in...